Results 11 to 20 of about 479 (110)

To be or not to be exclusive: the sutezolid story [PDF]

The Lancet Global Health, 2016
Response from Johns Hopkins University Johns Hopkins University is deeply committed to providing access to essential medicines, and has been working for years to advance the goal of ensuring that promising therapies for tuberculosis reach the market in an expeditious and accessible way.
Christy Wyskiel
exaly   +14 more sources

Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures [PDF]

Journal of Antimicrobial Chemotherapy
Abstract Background New and shorter regimens against multi-drug resistant tuberculosis (TB) remain urgently needed. To inform treatment duration in clinical trials, this study aimed to identify human pharmacokinetic equivalent doses, antimycobacterial and sterilizing activity of a novel regimen ...
Lindsey H M Te Brake, Norbert Heinrich, Elin M Svensson   +2 more
exaly   +10 more sources

Neuromyelitis optica causing vision loss during TB treatment with sutezolid: evidence of aberrant immunity following infection [PDF]

IJTLD Open
Contains fulltext : 319485.pdf (Publisher’s version ) (Open Access)
N.A. Glover, L. Paramo, S. Giangregorio, B. Sukwana, S.E. Koele, S. Charalambous, T. Ngwanto, S. Mashatole, D. Mudzengi, N. Heinrich, E.M. Svensson, F. Abdullah, G. Churchyard, R.S. Wallis   +13 more
doaj   +6 more sources

A Tandem Ring Closure and Nitrobenzene Reduction with Sulfide Provides an Improved Route to an Important Intermediate for the Anti-Tuberculosis Drug Candidate Sutezolid [PDF]

Organic Process Research and Development
Sutezolid is an in-development thiomorpholine derivative of the FDA-approved tuberculosis (TB) treatment linezolid. Current synthetic routes for preparing sutezolid start with thiomorpholine as a key structural building block; unfortunately, this material was identified as a major cost driver for the API, which will limit the potential uptake of this ...
Sarah Aleshire, Hanuman P Kalmode, Ryan Nelson   +2 more
exaly   +5 more sources

Single Ascending-Dose Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid in Healthy Adult Subjects. [PDF]

Antimicrobial Agents and Chemotherapy, 2022
The primary objective of the study was to evaluate the safety and tolerability of single oral doses of sutezolid tablets administered under fasting conditions in healthy adult subjects. The secondary objective was to determine the pharmacokinetics (PK) of sutezolid and two metabolites, PNU-101603 and PNU-101244.
Jerry R. Nedelman, Paul Bruinenberg
exaly   +4 more sources

Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB. [PDF]

J Antimicrob Chemother
Abstract Introduction Many drugs for the treatment of TB prolong the QTc interval, which is associated with an increased risk of developing a life-threatening arrhythmia known as torsades de pointes. Sutezolid and delpazolid are novel oxazolidinones with demonstrated bactericidal activity. We aimed to
Koele SE, Stoycheva K, Mtweve C, Manyama C, Mpagama S, Mhimbira F, Wallis R, Ntinginya NE, Liyoyo A, Huglin B, Minja LT, Wagnerberger L, Zumba T, Noreña I, Peter DD, Beattie T, Makkan H, Sloan DJ, Te Brake L, Aarnoutse RE, McHugh TD, Wildner L, Schildkraut J, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM, Heinrich N, PanACEA consortium .   +28 more
europepmc   +13 more sources

Population Pharmacokinetic/Pharmacodynamic Analysis of the Bactericidal Activities of Sutezolid (PNU-100480) and Its Major Metabolite against Intracellular Mycobacterium tuberculosis in Ex Vivo Whole-Blood Cultures of Patients with Pulmonary Tuberculosis [PDF]

Antimicrobial Agents and Chemotherapy, 2014
ABSTRACT Sutezolid (PNU-100480 [U-480]) is an oxazolidinone antimicrobial being developed for the treatment of tuberculosis. An active sulfoxide metabolite (PNU-101603 [U-603]), which reaches concentrations in plasma several times those of the parent, has been reported to drive the killing of extracellular ...
Tong Zhu, Sven O. Friedrich, Andreas Diacon, Robert S. Wallis   +3 more
openaire   +3 more sources

Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. [PDF]

PLoS ONE, 2012
There presently is no rapid method to assess the bactericidal activity of new regimens for tuberculosis. This study examined PNU-100480, TMC207, PA-824, SQ109, and pyrazinamide, singly and in various combinations, against intracellular M.
Robert S Wallis, Wesley Jakubiec, Mark Mitton-Fry, Lynn Ladutko, Sheldon Campbell, Darcy Paige, Annette Silvia, Paul F Miller   +7 more
doaj   +4 more sources

Oxazolidinone Antibiotics: Chemical, Biological and Analytical Aspects

Molecules, 2021
This review covers the main aspects concerning the chemistry, the biological activity and the analytical determination of oxazolidinones, the only new class of synthetic antibiotics advanced in clinical use over the past 50 years.
Claudia Foti, Anna Piperno, Angela Scala, Ottavia Giuffrè   +3 more
doaj   +2 more sources

Safety Profile of a Modified All-Oral Short-Term Regimen for Drug-Resistant Tuberculosis: an Experimental Assessment

Туберкулез и болезни лёгких
The objective: to evaluate the toxicity of bedaquiline and delamanid combined with linezolid or sutezolid (Szd) in a rat model.Materials and methods: Rats in the experimental groups (EG) were orally administered Bdq+Dlm+Lzd (EG1) or Bdq+Dlm+Szd (EG2 ...
G. N. Mozhokina, E. R. Pereverzeva, S. G. Yazeryan, V. A. Polozkova, A. E. Shchekotikhin, A. G. Samoilova   +5 more
doaj   +2 more sources